Clinical trials: Alopecia Areata
Alopecia Areata, Alopecia Totalis (AT)
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)
This study will compare two oral medicines-tofacitinib and methotrexate-for treating severe alopecia areata, including alopecia totalis (loss of all scalp hair) and alopecia universalis (loss of scalp and body hair).
- Conditions
- Alopecia Areata, Alopecia Totalis (AT), Alopecia Universalis
- Trial name
- TOFA-MTX-AA (NCT07406204)
- Testing
- Tofacitinib, Methotrexate
- Volunteers
- 78 people
- Sponsor
- Hayat Abad Medical Complex, Peshawar
Alopecia Areata
CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
Prospective, observational cohort study for subjects with AA under the care of a dermatology provider. Approximately 5,000 subjects and 100 clinical sites in North America will be recruited to participate with no defined upper…
- Trial name
- NCT05745389
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- CorEvitas
Alopecia Areata (AA)
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.
- Trial name
- NCT06060977
- Testing
- IMG-007
- Where
- 17 sites in United States, Canada
- Volunteers
- 29 people
- Sponsor
- Inmagene LLC
Vitiligo Vulgaris, Psoriasis
PALLAS Laser for Skin Diseases
The primary objective of this study is to get clinical experiences with the PALLAS laser in the treatment of skin conditions that respond well to UV light (vitiligo, psoriasis, alopecia areata, atopic dermatitis).
- Conditions
- Vitiligo Vulgaris, Psoriasis, Alopecia Areata, Atopic Dermatitis
- Trial name
- PALLAS-UV (NCT07250997)
- Testing
- UVB laser treatment
- Where
- Hungary
- Volunteers
- 50 people
- Sponsor
- Szeged University
Alopecia Areata(AA), Alopecia Areata (AA)
Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study
Rationale: Since the introduction of Janus kinase (JAK) inhibitors, there has been a significant advancement in the treatment of pediatric alopecia areata.
- Conditions
- Alopecia Areata(AA), Alopecia Areata (AA), Alopecia Totalis/Universalis, Alopecia Universalis (AU)
- Trial name
- COMPARE (NCT07381556)
- Testing
- Methotrexate, Cyclosporin (CSA)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Alopecia Areata
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
- Trial name
- NCT07133308
- Testing
- Deuruxolitinib
- Where
- 64 sites in United States, Canada
- Volunteers
- 355 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Alopecia Areata
DPCP for the Treatment of Alopecia Areata
This is an open labeled study to determine the response and characteristics, safety and efficacy, of the proprietary DPCP ointment composition as a topical immunotherapeutic agent for the treatment of extensive alopecia areata.
- Trial name
- NCT03651752
- Testing
- Diphenylcyclopropenone (DPCP) Ointment
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Minnesota
Alopecia Areata
Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata
Alopecia areata (AA) is an immunologically mediated disease characterized by non-scarring hair loss (Madni and Shapiro, 2000). AA is presented by rapid and complete hair loss in one or more round or oval patches, usually on the…
- Trial name
- NCT06327581
- Testing
- Lactic Acid, vit D, Triamcinolone Acetonide
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Zagazig University
Psoriasis, Atopic Dermatitis
LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12…
- Conditions
- Psoriasis, Atopic Dermatitis, Vitiligo, Alopecia Areata
- Trial name
- LANDSCAPE (NCT07336641)
- Testing
- Conventional Systemic Therapies, Biologic Therapies
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- Fondazione ISIDE
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Alopecia Areata
Comparison of Microneedling Along With Topical Vitamin D3 Versus Microneedling in Alopecia Areata
Alopecia areata is a common condition that causes sudden, patchy hair loss on the scalp and other body sites. It is believed to occur when the body's immune system mistakenly attacks the hair follicles, leading to hair loss that…
- Trial name
- NCT07243977
- Testing
- Microneedling + Vitamin D3, Microneedling
- Where
- Pakistan
- Volunteers
- 80 people
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Alopecia Areata
European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, severe alopecia areata.
- Trial name
- NCT05041803
- Testing
- CTP-543
- Where
- 39 sites in France, Germany and 3 more
- Volunteers
- 407 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Alopecia Areata
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
- Trial name
- NCT07205159
- Testing
- FB102
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 32 people
- Sponsor
- Forte Biosciences, Inc.
Alopecia Areata
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.
- Trial name
- NCT05522556
- Testing
- Ritlecitinib
- Sponsor
- Pfizer
Alopecia Areata
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03898479
- Testing
- CTP-543
- Where
- 91 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Alopecia, Alopecia Areata
Evaluation of the Efficacy and Safety of Oral Roflumilast Versus Intralesional Corticosteroids Injection (ILCs) in the Treatment of Alopecia Areata
Evaluation of the Efficacy and Safety of a drug called Oral Roflumilast versus Intralesional Corticosteroids Injection (ILCs) in the Treatment of Alopecia Areata.
- Trial name
- AA (NCT07174011)
- Testing
- Roflumilast, intralesional steroid
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Psoriasis (PsO), Vitiligo Vulgaris
Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis
Primary objective: The primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis…
- Conditions
- Psoriasis (PsO), Vitiligo Vulgaris, Atopic Dermatitis, Areata Alopecia
- Trial name
- STIGMADERM (NCT06801821)
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Alopecia Totalis/Universalis, Alopecia Areata(AA)
Rhofanib® (Tofacitinib) Safety and Effectiveness Evaluation
The goal of this observational study is to evaluate safety of Rhofanib® (Tofacitinib) in male or female participants with the age of 18 years or older having clinical diagnosis of Alopecia.
- Trial name
- NCT07101471
- Testing
- Tofacitinib
- Where
- Iran
- Volunteers
- 296 people
- Sponsor
- NanoAlvand
Alopecia Areata
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
This is a global Phase 2a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ritlecitinib in adults aged 18 to ≤50 years of age with ≥25% scalp hair loss due to Alopecia Areata (AA).
- Trial name
- Allegro2a (NCT04517864)
- Testing
- PF-06651600
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 71 people
- Sponsor
- Pfizer
Alopecia Areata, Acne Vulgaris
The Impact of Untreated Depression and Anxiety Among Patients With Skin Diseases in Jeddah, Saudi Arabia.
The goal of this observational study is to learn about the prevalence and severity of untreated depression and anxiety among adults with skin diseases in Jeddah, Saudi Arabia.
- Conditions
- Alopecia Areata, Acne Vulgaris, Psoriasis, Atopic Dermatitis (Eczema)
- Trial name
- NCT07046039
- Where
- Saudi Arabia
- Volunteers
- 215 people
- Sponsor
- King Abdulaziz University